2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
5
Neoplasms
5
Breast Neoplasms
5
Recurrence
2
Ovarian Neoplasms
2
Hypersensitivity
2
Brain Neoplasms
2
Squamous Cell Lung Cancer
1
Solid Tumors
1
Neoplasm Metastasis
1
Glioblastoma
1
Fanconi Anemia, Complementation Group D1
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Female
1
Advanced Solid Tumors
1
Advance Solid Tumors
1
Interventions
Tamoxifen
4
Exercise
3
pyrotinib
2
abemaciclib
2
Paclitaxel
2
Metformin
2
Letrozole
2
Cyclophosphamide
2
Control Groups
2
Capecitabine
2
Bupivacaine
2
Aromatase Inhibitors
2
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
palbociclib
1
iniparib
1
exemestane
1
durvalumab
1
darolutamide
1
Yoga
1
Waiting Lists
1
Vitamin D
1
Tumor Burden
1
Tretinoin
1
Trastuzumab
1
Tocopherols
1
Thioctic Acid
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Female
×
iniparib
×
Clear all
NCT01204125
2017-03-22
SOLTI NEOPARP
Sanofi
Phase 2
Completed
141 enrolled